Sanofi

With SK bioscience we’ve exciting news to share! We took a significant step by initiating the phase 3 clinical program for our 21-valent #pneumococcal conjugate vaccine candidate, the first pneumococcal vaccine with more than 20 serotypes to reach this stage of clinical development in infants and toddlers. In parallel, we’ve strengthened our partnership with SK bioscience, expanding our collaboration to develop, license, and bring to market next-generation pneumococcal vaccines. Pneumococcal disease remains a major global health challenge. #Innovation and #collaboration are key to addressing this urgent need. Read our press release: http://spkl.io/6048fjqZe

#DYK that multiple sclerosis (#MS) stands for “many scars?” One of the many “unseen scars” that take a toll on those living with MS is mental health. That’s why tracking the physical, cognitive and mood symptoms of MS is crucial to recognize if someone’s mental health is impacted. A big thank you to Luis Felipe O. and Amanda Montague for highlighting the importance of including mental health in the earliest conversations about clinical care. 🤝 ✨ Discover more about our commitment to helping reduce the burden of neurological diseases on the community. ⤵️ http://spkl.io/6043fbWrJ

New positive phase 2b results for investigational TL1A monoclonal antibody for the treatment of ulcerative colitis and Crohn's disease, the two most common forms of inflammatory bowel disease (IBD). Learn more about this data: http://spkl.io/6046fbYCI CC: Teva Pharmaceuticals

The FDA granted Breakthrough Therapy designation to our investigational treatment for adults with non-relapsing secondary progressive multiple sclerosis (nrSPMS). This milestone marks the first and only investigational BTK inhibitor in #MultipleSclerosis to be granted this designation by the FDA and highlights our unrelenting commitment to bringing treatment options to those with unmet needs. Read our press release ➡️ http://spkl.io/6043fwxXb

With McLaren Racing, we’re racing towards the future of science and health. 🏁 Since 2022, our partnership has infused a high-performance, race-inspired mindset into our Manufacturing & Supply operations. It has united two organizations that thrive in fast-paced, competitive environments, blending the speed, agility, and precision of Formula 1 with McLaren’s cutting-edge digital and analytical expertise. Together, we’ve redefined how we anticipate challenges and resolve issues. Yesterday, we were honored to welcome Zak Brown and Oscar Piastri to celebrate our commitment to excellence. Seeing a McLaren Formula 1 car in our office was an inspiring moment for our teams, showcasing the power of collaboration and precision in action. We also extend our congratulations for winning the 2024 Formula 1 Constructors’ Championship – a testament to their relentless pursuit of excellence that inspires us in our journey! 🤩 #WeNeverSettle #Innovation

FDA has granted Fast Track designation for our two combination vaccine candidates to prevent #influenza and #COVID19 infections. Both vaccine candidates combine two already licensed standalone vaccines with proven efficacy. This Fast Track designation recognizes the potential for our combination vaccine candidates to address the significant burden of influenza and COVID-19 on individuals and healthcare systems. Read our press release: http://spkl.io/6042fwVh8

At #ASH24, we showcased our commitment to evolving the treatment paradigm for rare blood disorders and blood cancers with two pivotal updates:    📌 Phase 3 data from our study in adults with #ImmuneThrombocytopenia (ITP) for our investigational treatment that has the potential to improve patient outcomes and become a first-in-class treatment in ITP.     📌 Phase 3 data in #MultipleMyeloma, demonstrating the potential of our combination regimens to help improve outcomes in newly diagnosed patients, regardless of transplant eligibility.     Read more about our news: https://lnkd.in/eDCYXngX

How can we build trust in #healthcare, together? 🤝 At Sanofi, trust is at the heart of everything we do — from our scientific research to our interactions patients, partners, and communities. Trust isn’t just a value we talk about; it’s a standard we work to uphold every day, guided by our Code of Conduct. As the world evolves, so does our Code. We’re updating and including essential areas like human rights, the responsible use of AI, and transparency on social media. Fostering a culture of accountability, openness, and continuous growth is essential to improve people's lives. 👀 Discover our Code of Conduct: http://spkl.io/6046fXtqn

We’re proud to announce the inauguration of our second cutting-edge #Modulus facility, now open in Singapore. This milestone reinforces our commitment to innovation, sustainability, and meeting global healthcare needs with agility and responsibility. Inaugurated by Singapore’s Minister for Health, Mr. Ong Ye Kung, this new facility is a testament to our vision for a sustainable and digitalized future in healthcare. With advanced green technologies like solar power, green electricity, and construction materials made from recycled content, this site showcases our dedication to eco-friendly innovation. As we celebrate this second Modulus facility, we look forward to continuing our mission to bring better health to more people, while paving the way for a sustainable future in healthcare. #WeNeverSettle

When cancer or critical illness touches one of our lives, it impacts all of us. 💙 Our Cancer & Work program offers a 360° global benefit that provides physical, emotional, financial and social support to Sanofians affected by cancer or critical illness, whether they are directly impacted, caregivers or colleagues. What began as a local initiative in France has now grown into a global network with 36 affinity groups, reflecting our commitment to a supportive workplace for all Sanofians. Together, we’re building a compassionate and resilient community. ✨ Learn more: https://lnkd.in/gFi2rm-r